PDCD1 and non-small cell lung carcinoma: Another ongoing phase II clinical trial (NCT04250246) evaluates guadecitabine, a novel DNMTi with improved pharmacokinetics causing genome-wide and nonspecific hypomethylation and inducing cell-cycle arrest at S-phase, alongside immune checkpoint blockage in patients with NSCLC and primary resistance to anti-PD-1/PD-L1 therapy.